Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ReGen Redux: Does a Troubled Medical Device Review Hold Any Lesson For Drugs?

This article was originally published in RPM Report

Executive Summary

The tainted FDA review and approval of a small medical device-a meniscal repair scaffolding--may have some important implications for drug reviews in the future and the checks-and-balances structure of the agency.

You may also be interested in...



Straight Talk About Cancer Drug Coverage

CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.

Straight Talk About Cancer Drug Coverage

CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.

Avandia and the Commercial Impact of FDA's Credibility Gap

GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.

Related Content

Topics

UsernamePublicRestriction

Register

PS080633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel